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Summary: We investigated the influence of cyclosporine A on the concentration of tissue factor pathway inhibitor
and von Willebrand factor antigen in plasma of heart transplant outpatients.
Tissue factor pathway inhibitor was quantified in plasma of blood donors (n = 50) and heart transplant outpatients
(n = 50) by a chromogenic substrate assay with a mean of 32.4 μg/l and 98.2 μ^, respectively. Von Willebrand
factor antigen was determined with an enzyme-linked immunoassay with a mean of 90.9% for blood donors and
184.5% in plasma of heart transplant recipients.
In addition, we investigated the effect of cyclosporine A on endothelial cell cultures over an incubation period of
four days. A dose-dependent effect of cyclosporine A on the release of endothelial tissue factor pathway inhibitor
and von Willebrand factor antigen was determined in a concentration range from 100 to 200 μg/l cyclosporine
A. The tissue factor pathway inhibitor and von Willebrand factor antigen concentrations in the cell culture superna-
tant increased during the incubation time according to the cyclosporine A concentration 2—3 fold and 2 fold, respec-
tively.
For a further elucidation of the cyclosporine A effect we investigated the influence of cremophor EL, the vehicle
of cyclosporine A. Cremophor EL alone did not increase the tissue factor pathway inhibitor release. However, the
release was enhanced 2—4 fold after co-stimulation with the calcium ionophore A 23187 (10~4mol/l) in a concentra-
tion-dependent mode.
We conclude that a generalized endothelial damage or activation is most probably caused by cyclosporine A and
its vehicle cremophor EL. This process probably depends upon the increase of cytosolic free calcium, as described
for the liberation of von Willebrand factor by endothelial cells.
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tor functions as a potent natural anticoagulant (7) regu-
lating tissue factor-mediated coagulation inhibition in
the extrinsic pathway (8). Tissue factor pathway inhibi-
tor directly inhibits factor Xa1) and, in a factor Xa-de-
pendent reaction, factor Vlla^/tissue factor catalytic
complex. Heparin enhances the tissue factor pathway in-
hibitor inhibition of factor Xa and increases the plasma
level of full-length tissue factor pathway inhibitor two
to four-fold (9). Addition of heparin to blood samples
does not change the tissue factor pathway inhibitor con-
centration. Therefore, the heparin-mediated increase
seems to be part of intracellular or cell-membrane asso-
ciated sources.
The von Willebrand factor, also known as the multimeric
macromolecular carrier of factor VIII coagulant activity,
is secreted by endothelial cells and platelets. It serves as
a connecting bridge between platelets and injury-ex-
posed vascular subendothelium (10—12). In laboratory
diagnostics the von Willebrand factor serves as a marker
of endothelial damage (13, 14). The cellular von Wille-
brand factor is either secreted directly from the cytosol
or after stimulation, when von Willebrand factor is re-
leased by von Weibel-Palade bodies.
We investigated the effect of cyclosporine A and/or
polyethoxylated castor oil (cremophor EL) on the re-
lease of tissue factor pathway inhibitor from endothelial
cells and used cell cultures to test this in vitro. Due to
water insolubility, cyclosporine A is diluted in cremo-
phor EL for intravenous injection and oral application
with Sandimmune. We used cyclosporine A and cremo-
phor EL at concentrations similar to in vivo levels dur-
ing treatment of heart transplant patients.
Materials and Methods
Blood collection
In this study we included post heart transplant patients up to 6
years after transplantation immunosuppressed by cyclosporine A
in therapeutical doses by oral administration. Blood samples were
obtained from 50 blood donors and 50 heart transplant outpatients
by drawing into citrated monovettes (9 vol blood to 1 vol
0.13 mol/1 trisodium citrate solution) or EDTA-prepared blood col-
lection tubes. The blood collection of heart transplant patients was
part of cyclosporine A monitoring every month. All samples were
stored at -70 °C after centrifugation for 10 min at 2500 g until fur-
ther use. After thawing, samples were centrifuged at 3000 g for
15 min to remove residual precipitates.
Measurement of tissue factor pathway inhibitor by a
chromogenic substrate assay
The inhibitory activity of tissue factor pathway inhibitor was mea-
sured by a modified chromogenic substrate assay based on the abil-
ity to inhibit factor X activation by factor Vila/tissue factor com-
plex. Tissue factor (25 μΐ) (dilution 1:80, Baxter, Unterschlei heim,
Germany), 25 μΐ factor VII (0.0125 U, Sigma, Deisenhofen, Ger-
!) Enzymes (clotting factors):
Factor VII (EC 3.4.21.2)
Factor X (EC 3.4.21.6)
many) were added to 25 μΐ 0.075 mol/1 CaCl2 and 25 μΐ factor X
(0.025 U, Sigma, Deisenhofen, Germany) and incubated for 15 min
at 37 °C under vigorous shaking. Samples (25 μΐ) (dilution up to
1:20) were added and after the same incubation conditions addi-
tional 25 μΐ factor X (0.4 U) were added, immediately. The chro-
mogenic reaction was started after further incubation (10 min,
37 °C) by addition of 25 μΐ synthetic substrate (2.7 mmol/1 N-ben-
zoyl-Ile-Glu-Gly-Arg-/7-nitroanilide, Chromogenix, Essen, Ger-
many). The absorbance was measured at 405 nm after 30 min sub-
strate incubation. The clotting factors and samples were diluted in
assay buffer containing 0.05 mol/1 Tris/HCl, 0.1 mol/1 NaCl and 10
g/1 human albumin (Armour Pharma, Eschwege, Germany), pH
8.0.
Our test system was calibrated with recombinant truncated two
domain tissue factor pathway inhibitor (domain 61 and 62) (Novo
Nordisk, Gentofte, Denmark) diluted in assay buffer. The inhibitory
activity of tissue factor pathway inhibitor in the substrate assay
was suppressed by addition of 100 ng monospecific goat anti-tissue
factor pathway inhibitor antibody (Novo Nordisk, Gentofte, Den-
mark) to the tested samples, thus indicating the specifity of the
chromogenic test system.
Quantification of von Willebrand factor antigen
Von Willebrand factor antigen was measured in EDTA-plasma by
a sandwich enzyme immunoassay (Boehringer Mannheim, Mann-
heim, Germany) and determined as percent of normal in plasma
samples and mU/1 in cell culture supernatant.
Quantification of cyclosporine A
Cyclosporine A was determined in EDTA whole blood by an auto-
mated monoclonal antibody radio immunoassay not detecting
cyclosporine metabolites (Ingstar/Sorin, D sseldorf, Germany).
Endothelial cell culture
Human umbilical vein endothelial cells (Promocell, Heidelberg,
Germany) were incubated in serum-free growth medium containing
human epidermal growth factor (10mg/l), bovine brain extract
(12 mg/1), hydrocortisone (1 mg/1) and antibiotics (50 mg/1) (Pro-
mocell, Heidelberg, Germany). Human umbilical vein endothelial
cells at the second passage after isolation were passaged in a solu-
tion of 0.5 g/1 trypsine and 0.2 g/1 EDTA (all Sigma, Deisenhofen,
Germany) and seed in petri dishes of 60 mm diameter and grown
to 80% confluence. The culture medium was refreshed before the
cells were incubated with cyclosporine A (Sandimmun, Sandoz,
Basle, Switzerland) in a concentration range from 20 to 200 mg/1
and/or cremophor EL (Sigma, Deisenhofen, Germany) from 1 to
50 mg/1.
Furthermore, endothelial cells were stimulated with calcium iono-
phore A 23187 (10~4mol/l) (Sigma, Deisenhofen, Germany) alone
or in combination with cremophor EL (0—10 mg/1). Constitutive
tissue factor pathway inhibitor release in unstimulated cells was
tested in cell culture medium as described above (Promocell, Hei-
delberg, Germany).
Over a period of four days, tissue factor pathway inhibitor contain-
ing supernatants were removed from whole plate per day for quan-
tification. The cell number of every plate was counted microscopi-
cally.
Homogeneity, morphology and differentiation of the cultured cells
were determined by microscopical inspection and during cell
growth by flow cytometry using a monoclonal antibody directed
against E-selectin (ELAM-1, Biozol, Eching, Germany) as a spe-
cific endothelial surface marker and HLA-ABC monoclonal anti-
body (Dianova, Hamburg, Germany) in a Becton-Dickinson FACS-
can analyzer with CELLQuest software. Lactate dehydrogenase ca-
talytic concentration was determined to exclude limited cell death
and was measured with a Syncron CX7 clinical chemistry analyzer
(Beckman, CA). We measured the proliferative activity of the cell
cultures under the influence of stimulating agents by a Cell-Prolif-
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eration-Kit (Boehringer Mannheim, Mannheim, Germany). All
buffers and reagents were negative for pyrogenes or endotoxins.
Statistical analysis
All statistical analyses between patient groups were performed by
the Kolmogoroff-Smirnov-test and the median test to evaluate sta-
tistically significant differences between collectives. The Komolgo-
roff-Smirnov-test is most stringent for not normally distributed in-
dependent samples.
Values of p < 0.001 were considered to be statistically significant.
For all groups and measurements we calculated the 90%-range,
mean value and standard deviation.
Results
Measurement of cyclosporine A in plasma of
heart transplant outpatients
The cyclosporine A concentration in stable heart
transplant outpatients was determined in a range from
130—280 μ§/1 representing the application of therapeuti-
cal doses by oral application. This concentration of
cyclosporine A was chosen as the basis for cell culture
experiments, as well as cremophor EL in an equivalent
dose.
Measurement of tissue factor pathway
inhibitor in plasma samples
Tissue factor pathway inhibitor was quantified in plasma
samples of 50 blood donors (25 of each sex from 18—60
years). The standard deviation and mean value were
10.3 μg/l and 32.4 μg/l, respectively. No significant sex
or age dependencies were observed. Addition of
200 μg/l cyclosporine A to the plasma samples showed
no effect on the tissue factor pathway inhibitor determi-
nation in the chromogenic substrate assay.
In contrast, the determination of tissue factor pathway
inhibitor in 50 stable heart transplant immunosuppressed
patients showed a 2—4 fold increased tissue factor path-
way inhibitor concentration. The standard deviation and
mean concentration were 28.8 μg/l and 98.2 μg/l,
respectively (fig. 1). A correlation between cyclosporine
A and tissue factor pathway inhibitor concentrations was
not observed. The tissue factor pathway inhibitor con-
centrations determined with our test system were signifi-
cantly lower than expected. However, a clear difference
between normal individuals and heart transplant patients
was shown.
Measurement of von Willebrand factor
antigen in plasma samples
In heart transplant outpatients we also found consider-
ably enhanced levels of von Willebrand factor antigen.
The standard deviation and mean value of von Wille-
brand factor antigen in heart transplant patients were
90.7% and 185%, respectively. In blood donors the stan-
dard deviation was 29.9% and the mean value was 91%
(fig. 2). No sex or age dependencies were observed. A
correlation between von Willebrand factor antigen and
cyclosporine A concentration was not observed.
Endothelial cell culture
Flow cytometric analysis showed constant homogeneity
of the cells stained with ELAM-1 and HLA-ABC mo-
noclonal antibody during four days incubation. Lactate
dehydrogenase concentration was constant in all tested
samples over the four days (25—30 U/l).
The proliferative activity of the cell culture was constant
during the incubation with cremophor EL (fig. 3) for
14 h. A dose-dependent effect was not observed. Incuba-
tion with the ionophore A 23187 (10~4mol/l) alone or
in combination with cremophor EL decreased the prolif-
erative activity after Ih (fig. 4).
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Fig. 1 Tissue factor pathway inhibitor concentration in titrated
plasma of heart transplant patients (n = 50) compared to normal
plasma from blood donors (n = 50) measured by a chromogenic
substrate assay. The mean tissue factor pathway inhibitor concen-
tration (bar) in organ transplant patients (90 μ§/1) is approximately
3-fold higher than in normal plasma (30 μg/l). The 90%-range in
blood donors is 18—52 μg/l compared to 51 —153 μ^ in immuno-
suppressed patients.
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Fig. 2 Plasma concentration of von Willebrand factor antigen.
The mean concentration and 90% range of von Willebrand factor
antigen were 91% and 53—146% in blood donors (n = 50) in con-
trast to 185% and 67-376% in heart transplant patients (n = 50).
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Fig. 3 Determination of endothelial cell proliferation (105 cells
per well) in response to different concentrations of cremophor EL
with and without calcium ionophore A 23187. The absorbance
(Assonm) represents the redox reaction of MTT to formazan salt by
metabolic active cells.
O-O cremophor EL (0-10 mg/l), φ-φ cremophor EL (0-10
mg/l) and ionophore A 23187 (10~4 mol/1).
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Fig. 4 Determination of endothelial cell proliferation (105 per
well). Cells were incubated with different concentrations of cremo-
phor EL (0-10 mg/l) and ionophore A 23187 over a period of 14
hours. Endothelial cells ·—· without additives, ο—ο with 5 mg/l
cremophor EL, D—D 10 mg/l cremophor EL, ·—· 10~4 mol/1 io-
nophore A 23187, A-A 5 mg/l cremophor EL + 10~4 mol/1
A 23187 and Δ-Δ 10 mg/l cremophor EL + 10~4 mol/1 iono-
phore A 23187.
Measurement of tissue factor pathway
inhibitor in endothelial cell culture medium
To investigate the in vitro effect of cyclosporine A, en-
dothelial cells were cultivated with different concentra-
tions (50—200 μ§/1) of cyclosporine A over a period of
four days. Incubation with 20 μ§/1 and 50 μ§/1 cyclo-
sporine A showed no significant tissue factor pathway
inhibitor release in the cell culture supernatant (tissue
factor pathway inhibitor, 69—195 ng/105 cells and
91 —183ng/105 cells during the incubation period) in
comparison to control medium without cyclosporine A
(tissue factor pathway inhibitor, 66—183 ng/105 cells
during the incubation period). Addition of 100 μg/l to
200 μg/l cyclosporine A showed an increased release of
tissue factor pathway inhibitor into the culture medium
with 150-436 ng/105 cells and 190-652 ng/105 cells
over a period of four days (fig. 5).
Cremophor EL (50 μg/l) alone did not alter the release
of tissue factor pathway inhibitor compared to constitu-
tive concentrations over a period of 24 hours. Increased
tissue factor pathway inhibitor concentrations were ob-
served after stimulation with the ionophore A 23187
(120-160 ng/105 cells). When cremophor EL and A
23187 were added in combination, an elevated tissue
factor pathway inhibitor concentration was detected
(190-265 ng/105 cells) (fig. 6).
Measurement of von Willebrand factor
antigen in endothelial cell culture
supernatant
We also observed a significant correlation of von Wille-
brand factor antigen and cyclosporine A in cell culture
medium dependent upon the cyclosporine concentration.
Von Willebrand factor antigen concentration did not alter
significantly the first three days after cyclosporine A sti-
mulation (3—9 mU/105 cells). A significant dose depen-
dent effect of cyclosporine A was determined on day 4.
After addition of 50 μg/l and 100 μg/l cyclosporine A
the von Willebrand factor antigen concentrations
increased to 19 mU/105 cells and 22 mU/105 cells. Cells
incubated with 20 μg/l cyclosporine A concentration or
without cyclosporine A showed a lower von Willebrand
factor antigen concentration in the cell culture superna-
tant with 10 mU/105 cells and 6 mU/105 cells (fig. 7).
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Fig. 5 Measurement of the released tissue factor pathway inhibi-
tor in the cell culture supernatant of endothelial cells (ng/105 cells)
over a period of 4 days. Cells were incubated with different con-
centrations of cyclosporine A.
x-x without cyclosporine A, o-o with 20 μg/l cyclosporine A,
D-D 50 μg/l cyclosporine A, ·-· 100 μg/l cyclosporine A and
·—· 200 μg/l cyclosporine A.
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Fig. 6 Measurement of released tissue factor pathway inhibitor in
the cell culture supernatant of endothelial cells (105 per well) after
incubation with cremophor EL and the calcium ionophore
A 23187.
ο—ο cells without additives, ·—· with cremophor EL (10mg/l),
·—· 10~4 mol/1 calcium ionophore A 23187, and D-D cremophor
EL (10 mg/1) + 10~4 mol/1 calcium ionophore A 23187.
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Fig. 7 Measurement of the von Willebrand factor antigen concen-
tration in the culture supernatant of endothelial cells (105 per well).
The cells were incubated over a period of 4 days. Each value repre-
sents a separate petri dish.
σ—ο cells cultivated without cyclosporine A, ·—· with 20 μ§Λ
cyclosporine A, D—D with 50 μ§/1 cyclosporine A and ·—· with
100 μ§/1 cyclosporine A.
Discussion
Tissue factor pathway inhibitor is the main natural
plasma inhibitor of the extrinsic pathway of coagula-
tion (15,16). Among other cell types tissue factor path-
way inhibitor has been shown to be expressed by
endothelial cells (17,18), megakaryocytes, chondro-
cytes and synovial cells (19,20). The extrinsic pathway
is initiated by the tissue factor/factor VII complex,
which is inhibited by tissue factor pathway inhibitor.
Thus it is involved in prolonging factor Xa mediated
coagulation time.
In the present study we have investigated the tissue
factor pathway inhibitor concentration in immunosup-
pressed heart transplant patients. In comparison to blood
donors, the tissue factor pathway inhibitor concentration
in transplant patients was significantly higher. The mean
tissue factor pathway inhibitor concentration of the
blood donors was 32 μ§/1, wherease the mean tissue
factor pathway inhibitor concentration of immunosup-
pressed patients was 98 μg/l. Our chromogenic test sys-
tem was calibrated with recombinant truncated tissue
factor pathway inhibitor and was sufficient for the mea-
surement of relative tissue factor pathway inhibitor con-
centration in transplant patients and normal individuals.
However, the tissue factor pathway inhibitor concentra-
tions determined with our chromogenic substrate assay
were lower than published elsewhere (21,22). In contrast
to other chromogenic assays we used recombinant tissue
factor pathway inhibitor for calibration. The specific in-
hibitory activity of recombinant tissue factor pathway
inhibitor is higher than in normal pooled plasma result-
ing in lower tissue factor pathway inhibitor values in the
chromogenic substrate assay.
In immunosuppressed patients a 2—4 fold increase of
the inhibitory activity of tissue factor pathway inhibitor
was observed. The mean therapeutic cyclosporine A
concentration was 200 μg/l. Cytotoxic effects of cyclo-
sporine on endothelial cells are well known (1). There-
fore, the increase of tissue factor pathway inhibitor in
plasma of heart transplant patients let us suggest that
cyclosporine A influences the tissue factor pathway in-
hibitor release from the endothelium into the extracellu-
lar space. Thus the concentration of released free tissue
factor pathway inhibitor (not bound to lipoproteins) may
reflect the damage of the endothelium which is consid-
ered to be the origin of plasma tissue factor pathway
inhibitor. This is confirmed because addition of cyclo-
sporine A to plasma samples showed no tissue factor
pathway inhibitor elevation. If cyclosporine A upregu-
lated the synthesis of tissue factor pathway inhibitor, we
would expect an increase of total tissue factor pathway
inhibitor in plasma. The chromogenic assay system used
in this study could not answer this question, because the
increased concentration of only functional active tissue
factor pathway inhibitor was determined.
As von Willebrand factor is also a marker of endothelial
cell damage processes (23, 24), we also measured
plasma von Willebrand factor antigen in plasma of
cardiac transplant patients. As with tissue factor pathway
inhibitor, the von Willebrand factor antigen plasma
levels were also increased in these individuals compared
to healthy blood donors (tab. 1).
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Tab. 1 Tissue factor pathway inhibitor and von Willebrand factor
antigen concentrations in blood donors (n = 50) and heart
transplant outpatients (n = 50). The data include the mean value
and 90% range.
Mean
SD
Blood
donors
(n = 50)
[μβ/1]
32.4
10.3
Heart
transplant
patients
(n = 50)
[μβ/Ι]
98.2
28.8
Blood
donors
(n = 50)
[%]
90.9
29.9
Heart
transplant
pantients
(n = 50)
[%]
184.5
90.7
From a pathophysiological point of view, the von Wille-
brand factor fosters platelet adhesion to damaged endo-
thelium or exposed subendothelium. In persistently
increased concentrations it may augment the cascade of
events leading to transplant atherosclerosis. Newer in-
vestigations point to a role of von Willebrand factor as
a coronary atherosclerosis risk (25).
Our investigations with endothelial cell cultures demon-
strated a dose-dependent effect of cyclosporine A on the
cellular tissue factor pathway inhibitor and von Wille-
brand factor antigen release into the supernatant. Similar
results were described with low molecular weight hepa-
rin on endothelial cells (26). Since no cell differentiation
or cell damage was determined by flow cytometry, by
microscopic inspection and by the measurement of lac-
tate dehydrogenase catalytic activity concentration in the
cell culture medium, we conclude that no cytotoxic ef-
fects occurred during incubation with cyclosporine A in
different concentrations. Therefore, we conclude that the
release of tissue factor pathway inhibitor and von Wille-
brand factor antigen into the plasma of immunosup-
pressed patients is not a result of a severe vascular endo-
thelial cell injury. The enhanced release can also be
shown by coincubation with cremophor EL and non-
physiological agonist calcium ionophore A 23187.
These results demonstrate that cremophor EL is the
stimulating agent and cyclosporine A may function as
cytosolic calcium modulator. Abraham and coworker
(27) previously described the effect of cremophor EL in
a rat model. In these experiments a reduction in kidney
interlobular arterial blood flow, decreased cardiac output
and induced hypotension were observed, thus indicating
that cremophor EL becomes active when administered
orally or intravenously. Furthermore, cyclosporine A is
described to increase the Ca2+ concentration in vascular
smooth muscle cells (28), hepatocytes (29) and mesan-
gial cells (30). Therefore, cyclosporine A seems to be
responsible for the calcium influx to or release from in-
tracellular stores.
Taken together, our results let us suggest that cyclosporine
A and its vehicle cremophor EL stimulate endothelial
cells in the same way and induce tissue factor pathway in-
hibitor release into the extracellular space. These findings
are in accordance with the enhanced von Willebrand
factor antigen release, as described earlier (1—3).
In contrast to von Willebrand factor, which has pro-hae-
mostatic and atherogenic properties, tissue factor path-
way inhibitor is a coagulation inhibitor and thus anti-
thrombotic and probably anti-atherogenic.
The consequences of long term plasma elevation of tis-
sue factor pathway inhibitor and von Willebrand factor
antigen are difficult to calculate. Further studies on other
endothelial-derived proteins in cyclosporine treated pa-
tients in connection with their coronary status are
needed.
We recommend the measurement of endothelial derived
proteins in clinical studies of new immunosuppressive
agents (e. g. tacrolimus).
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